Skip to main content

Advertisement

SpringerLink
Log in

A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The purpose of this study was to develop an in situ immune marker model to predict postoperative oncological outcomes in patients with colorectal cancer (CRC).

Methods

Immunohistochemistry for 13 immune cell markers was performed on tumor tissue microarrays from 300 CRC patients who underwent curative resection from January 2000 to January 2006. Genetic algorithm was applied for the construction of an in situ immune marker model.

Results

The infiltration of CD3+ cells, CD45RO+ cells, and FOXP3+ cells, but not the infiltration of Tryptase+ cells, in the tumor was significantly associated with better clinical outcome in overall survival (OS) and disease-free survival (DFS) of CRC patients, as assessed by univariate analysis (P < 0.05). Based on the genetic algorithms, a total of 6 markers, including CD3, CD45RO, IL17, CD15, Tryptase, and FOXP3, were selected to construct an immune marker model. Our model was identified to have an independent predictive capability for both OS and DFS in Cox multivariable model (P < 0.001). This was further confirmed by the ROC analysis (area under curve: OS, 0.669; DFS, 0.684).

Conclusions

The in situ immune marker model constructed in this study provides a novel approach to identify CRC patients who were at an increased risk for poor oncological outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004; 96:1420–5.

    Article  PubMed  Google Scholar 

  3. Nitsche U, Maak M, Schuster T, et al. Prediction of prognosis is not improved by the seventh and latest edition of the TNM classification for colorectal cancer in a single-center collective. Ann Surg. 2011;254:793–800; discussion 800–1.

    Article  PubMed  Google Scholar 

  4. Zlobec I, Karamitopoulou E, Terracciano L, et al. TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS One. 2010;5:e14282.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  PubMed  Google Scholar 

  6. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.

    Article  CAS  PubMed  Google Scholar 

  7. Garcia-Martinez E, Gil GL, Benito AC, et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16:488.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015;107:dju435.

  9. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.

    Article  CAS  PubMed  Google Scholar 

  10. Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33:335–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Wu XR, He XS, Chen YF, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol. 2012;106:130–7.

    Article  CAS  PubMed  Google Scholar 

  13. Faith DA, Isaacs WB, Morgan JD, et al. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate. 2004;61:215–27.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.

    Article  CAS  PubMed  Google Scholar 

  15. Ooi CH, Tan P. Genetic algorithms applied to multi-class prediction for the analysis of gene expression data. Bioinformatics. 2003;19:37–44.

    Article  CAS  PubMed  Google Scholar 

  16. Rothberg BEG, Berger AJ, Molinaro AM, et al. Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol. 2009;27:5772–80.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Tejpar S, Bertagnolli M, Bosman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist. 2010;15:390–404.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375:1030–47.

    Article  PubMed  Google Scholar 

  19. Mlecnik B, Bindea G, Angell HK, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014;6:228ra237.

  20. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–95.

    Article  CAS  PubMed  Google Scholar 

  21. Mlecnik B, Bindea G, Pages F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 2011;30:5–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883–6.

    Article  CAS  PubMed  Google Scholar 

  23. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.

    Article  CAS  PubMed  Google Scholar 

  24. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222:350–66.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Frey DM, Droeser RA, Viehl CT, et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer. 2010;126:2635–43.

    CAS  PubMed  Google Scholar 

  26. Malfettone A, Silvestris N, Saponaro C, et al. High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med. 2013;17:1025–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610–8.

    Article  PubMed  Google Scholar 

  28. Hendriks Y, Franken P, Dierssen JW, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol. 2003;162:469–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Xu J, Ding T, He Q, et al. An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. J Hepatol. 2012;57:313–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Xueqin Wang (Sun Yat-sen University) and Dr. Patrick Tan (Genome Institute of Singapore) for valuable insights in data analysis. This work was supported by National Key Clinical Discipline, National High Technology Research and Development Program (863) of China (No. 2012AA02A520), International S&T Cooperation Program of China (ISTCP) (No. 2013DFG32990), National Natural Science Foundation of China (NSFC) (No. 81400603), Science and Technology Program of Guangzhou, China (No. 2013J4100113), and Guangdong Department of Science & Technology Translational Medicine Center Grant (No. 2011A080300002).

Disclosure

All the authors declared that there’s no conflict of interest.

Author information

Author notes

    Authors and Affiliations

    1. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

      Yufeng Chen MD, Xianrui Wu MD, PhD, Xiaosheng He MD, PhD, Yang Zeng MD, PhD, Lei Wang MD, PhD, Jianping Wang MD, PhD, Ping Lan MD, PhD & Xiaojian Wu MD, PhD

    2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

      Yufeng Chen MD, Ruixue Yuan PhD, Xianrui Wu MD, PhD, Lei Wang MD, PhD, Jianping Wang MD, PhD, Ping Lan MD, PhD & Xiaojian Wu MD, PhD

    3. Guangdong Institute of Gastroenterology, Guangzhou, China

      Ruixue Yuan PhD, Lei Wang MD, PhD, Jianping Wang MD, PhD, Ping Lan MD, PhD & Xiaojian Wu MD, PhD

    4. Department of Pathology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

      Xinjuan Fan MD, PhD

    Authors
    1. Yufeng Chen MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Ruixue Yuan PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Xianrui Wu MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Xiaosheng He MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Yang Zeng MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Xinjuan Fan MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Lei Wang MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Jianping Wang MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Ping Lan MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Xiaojian Wu MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Ping Lan MD, PhD or Xiaojian Wu MD, PhD.

    Additional information

    Yufeng Chen, Ruixue Yuan, and Xianrui Wu have contributed equally to this paper.

    Electronic Supplementary Material

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Chen, Y., Yuan, R., Wu, X. et al. A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer. Ann Surg Oncol 23, 826–832 (2016). https://doi.org/10.1245/s10434-015-4889-1

    Download citation

    • Received:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1245/s10434-015-4889-1

    Keywords

    Search

    Navigation